Abstracts Archive - Page 232 of 2607 - ACR Meeting Abstracts

Abstract Number: 0366 • ACR Convergence 2024
Factors Associated with Participation in Rheumatology Clinical Trials: A UK-based Study
Koushan Kouranloo¹ and Chris Wincup², ¹Internal Medicine Resident., London, United Kingdom, ²King's College Hospital, London, United Kingdom
Background/Purpose: Clinicians are encouraged to consider patient preferences for offering face-to-face vs virtual consultations. This adaptability is particularly important to rheumatologists caring for patients with…
Abstract Number: 0390 • ACR Convergence 2024
Treatment Effectiveness Following Switching from Initial TNF Inhibitor in Juvenile Idiopathic Arthritis
Mei-Sing Ong¹, Sarah Ringold², Melissa Mannion³, Marc Natter⁴ and Yukiko Kimura⁵, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ²Washington University, Seattle, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Boston Children's Hospital, Boston, MA, ⁵Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Although the increasing availability of biologic therapies has significantly improved outcomes for patients with JIA, a substantial proportion of patients require switching from the…
Abstract Number: 2450 • ACR Convergence 2024
Disease Progression in Anti-Centromere Positive Systemic Sclerosis Patients
Eva Hoekstra¹, S. Ahmed², David Ueckert³, Nina Ajmone Marsan³, Philippine Kiès³, M.K. Ninaber³, Marlies Heuvers³, Miranda Geelhoed³, Thomas Huizinga⁴ and Jeska de Vries-Bouwstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Leids Universitair Medisch Centrum, Leiden, Netherlands, ⁴Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: Disease progression in systemic sclerosis (SSc) is characterized by severe and early progression in anti-topoisomerase (ATA) positive diffuse cutaneous patients and typically involves lung…
Abstract Number: 0376 • ACR Convergence 2024
Preliminary Results of the Ondansetron Pre-medication Trial in Juvenile Idiopathic Arthritis: A Pragmatic Randomized Controlled Trial Nested in the CAPRI Registry
Gaelle Chedeville¹, Heinrike Schmeling², Jean-Philippe Proulx-Gauthier³, Michelle Batthish⁴, Jean Jacques De Bruycker⁵, Brian Feldman⁶, Roberta A Berard⁷, Roxana Bolaria⁸, Amieleena Chhabra⁹, Lily Lim¹⁰, Adam Huber¹¹, Matthew Berkowitz¹², Thomas Loughin¹² and Jaime Guzman¹³, and CAPRI Registry Investigators, ¹The Montreal Children's Hospital, Montreal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³CHU de Quebec - Universite Laval, Quebec, QC, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵UNIVERSITY OF MONTREAL, Montreal, QC, Montreal, QC, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁷London Health Sciences Centre, London, ON, Canada, ⁸Victoria Arthritis Center, Victoria, BC, Canada, ⁹University of British Columbia, Penticton, BC, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹IWK Health Centre, Halifax, NS, Canada, ¹²Simon Fraser University, Burnaby, BC, Canada, ¹³University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: About 50% of children with Juvenile Idiopathic Arthritis (JIA) receiving methotrexate (MTX) develop MTX intolerance with severe anticipatory nausea/vomiting and avoidance behaviors. Intolerance often…
Abstract Number: 0381 • ACR Convergence 2024
Two- and 3-Year Outcomes of the Childhood Arthritis and Rheumatology Research Alliance FROST Study of New-onset Systemic JIA Treatment
Timothy Hahn¹, George Tomlinson², Yukiko Kimura³, Vincent Del Gaizo⁴, Carlos Valdes⁵ and Timothy Beukelman⁶, and for the CARRA FROST Investigators, ¹Penn State Childrens Hospital, Hershey, PA, ²University of Toronto, Toronto, ON, Canada, ³Hackensack Meridian School of Medicine, New York, NY, ⁴Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁵Genentech, Davie, FL, ⁶University of Alabama at Birmingham, Birmingham, AL

Background/Purpose: The FiRst Line Options for sJIA Treatment (FROST) trial was a prospective observational study designed to compare the effectiveness of 4 Childhood Arthritis and…
Abstract Number: 0380 • ACR Convergence 2024
Joint Acoustic Emissions as a Digital Biomarker for Knee Inflammation in Juvenile Idiopathic Arthritis: A Pilot Study Using Musculoskeletal Ultrasound as Ground Truth
Quentin Goossens¹, Christopher Nichols¹, Diana Sofia Villacis-Nunez², Lori Ponder³, Omer Inan⁴ and Sampath Prahalad⁵, ¹Georgia Institute of Technology, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Georgia Institute of Technology, Marietta, GA, ⁵Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic childhood arthropathy affecting 1 in 1000 children under 16, classified into seven categories by ILAR. Commonly, JIA…
Abstract Number: 2646 • ACR Convergence 2024
Rare Variants in the IL1RAP Gene Implicate the IL-1 Signaling Pathway in the Pathogenesis of Systemic Sclerosis in African and European Ancestries
Yosuke Kunishita¹, Urvashi Kaundal², Martin Kerick³, Ryan Routsong⁴, Justin Lack⁴, Ami Shah⁵, Maureen Mayes⁶, Daniel Shriner⁷, Ayo P. Doumatey⁷, Amy Bentley⁷, Robyn Domsic⁸, Thomas Medsger, Jr⁹, Paula Ramos¹⁰, Richard Silver¹¹, Virginia Steen¹², John Varga¹³, Vivien Hsu¹⁴, Lesley Ann Saketkoo¹⁵, Dinesh Khanna¹³, Elena Schiopu¹⁶, Jessica Gordon¹⁷, Lindsey Criswell¹⁸, Heather Gladue¹⁹, Chris Derk²⁰, Elana Bernstein²¹, S. Louis Bridges¹⁷, Victoria Shanmugam²², Lorinda Chung²³, Suzanne Kafaja²⁴, Reem Jan²⁵, Marcin Trojanowski²⁶, Avram Goldberg²⁷, Benjamin Korman²⁸, James W. Thomas²⁹, Elaine Remmers³⁰, Adebowale Adeyemo⁷, Charles Rotimi⁷, Fredrick Wigley³¹, Francesco Boin³², Javier Martin³, Daniel Kastner³³ and Pravitt Gourh³⁴, ¹Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Chevy Chase, MD, ³Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, ⁴Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ⁵Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁶UTHealth Houston Division of Rheumatology, Houston, TX, ⁷Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁹Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ¹²Georgetown University School of Medicine, Washington, DC, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Department of Medicine, Rheumatology Division, Rutgers-RWJ Medical School, South Plainfield, NJ, ¹⁵New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, ¹⁶Division of Rheumatology, Medical College of Georgia at Augusta University, Martinez, GA, ¹⁷Division of Rheumatology, Weill Cornell Medical College, New York, NY, ¹⁸Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Bethesda, MD, ¹⁹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²⁰Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²¹Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ²²Office of Autoimmune Disease Research, Office of Research on Women's Health, National Institutes of Health, Great Falls, VA, ²³Stanford University, Woodside, CA, ²⁴Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²⁵Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, ²⁶Department of Rheumatology, Boston University School of Medicine, Boston, MA, ²⁷NYU Langone Health - NYU Hospital for Joint Diseases, Lake Success, NY, ²⁸University of Rochester, Rochester, NY, ²⁹NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³⁰Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³¹Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ³²Cedars-Sinai Medical Center, Los Angeles, CA, ³³National Human Genome Research Institute, Bethesda, MD, ³⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by systemic inflammation and fibrosis. Interleukin-1 receptor accessory protein (IL1RAP) is a co-receptor for the Interleukin-1…
Abstract Number: 0377 • ACR Convergence 2024
Improving Self-Management Support in Patients with Juvenile Idiopathic Arthritis
Julia Harris¹, Leslie Favier², Emily Fox³, Michael Holland³, Cara Hoffart⁴, Maria Ibarra³, Jordan Jones⁴, Susan Parish², Kara Remick-Erickson² and Ashley Cooper⁴, ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Kansas City, Kansas City, ³Children's Mercy Hospital, Kansas City, MO, ⁴Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Self-management support (SMS) is one of the key elements of the Chronic Care Model as it is an important aspect of the care for…
Abstract Number: 0378 • ACR Convergence 2024
Disparate Disease Activity Outcomes Associated with Demographic Variables in Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Cagri Yildirim-Toruner⁴, Kerry Ferraro⁵, Erik Friedrichsen⁶, Michelle Batthish⁷, Jon Burnham⁸, Danielle Fair⁹, Suhas Ganguli¹⁰, Mileka Gilbert¹¹, Beth Gottlieb¹², Tzielan Lee¹³, Daniel Lovell¹⁴, Melissa Mannion¹⁵, Edward Oberle¹⁶, Nancy Pan¹⁷, Linda Ray¹⁸, Michael Shishov¹⁹, Mary Toth²⁰ and Esi Morgan²¹, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children’s Hospital, Hershey, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁵JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁶Seattle Children's Hospital, Seattle, ⁷McMaster Children's Hospital, Hamilton, ON, Canada, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ¹⁰Hackensack University Medical Center, Hackensack, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Cohen Children's Medical Center, Lake Success, NY, ¹³Stanford University School of Medicine, Palo Alto, CA, ¹⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵University of Alabama at Birmingham, Birmingham, AL, ¹⁶Nationwide Children's Hospital, Columbus, OH, ¹⁷Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ¹⁸University of Mississippi Medical Center, Jackson, MS, ¹⁹Phoenix Children's Hospital, Phoenix, AZ, ²⁰Nemours Foundation, Orlando, FL, ²¹Seattle Children's Hospital, Seattle, WA
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a North American learning health network focused on improving outcomes in patients with juvenile…
Abstract Number: 0362 • ACR Convergence 2024
Development of a Theory-based Digital Messaging Program to Reduce Fatigue in Systemic Lupus Erythematosus
Anna Deck¹, Paula Caras², Kiran Singh³, Monique Gore-Massy⁴, Faye Chiu⁵, Sara Folta⁶ and Shanthini Kasturi³, ¹Tufts University School of Medicine, Portland, ME, ²Tufts University School of Medicine, Boston, MA, ³Tufts Medical Center, Boston, MA, ⁴Lupus Foundation of America, New Jersey, ⁵N/A, New York City, NY, ⁶Tufts University/Tufts University Friedman School of Nutrition, Boston, MA
Background/Purpose: Fatigue is the single most prevalent symptom of systemic lupus erythematous (SLE), affecting 80-90% of patients, and is often refractory to pharmacologic therapy. Non-pharmacologic…
Abstract Number: 2654 • ACR Convergence 2024
Adapting and Testing a Cognitive Rehabilitation Intervention Tailored for People with Systemic Sclerosis: Acceptability, Feasibility, & Impact on Health-related Outcomes
Yen Chen¹, Mary Alore², Dinesh Khanna¹ and Susan Murphy³, ¹University of Michigan, Ann Arbor, MI, ²Self-employed, TROY, MI, ³University of Michigan, Plymouth, MI
Background/Purpose: Cognitive dysfunction affects up to 87% of individuals with systemic sclerosis (SSc), often significantly impairing their work and daily activities and exacerbating other symptoms…
Abstract Number: 0763 • ACR Convergence 2024
Transcriptional Analysis of Both Normal and Abnormal TABs in Biopsy-proven GCA Reveals a Shared Gene Expression Profile Compared to Clinically Diverse Controls
Ingrid Lindquist¹, Dongseok Choi², Suzanne Fei³, Kiana Vakil-Gilani⁴, Daniela Ghetie¹, David Wilson⁵, Diva Salomao⁶, Hillary Stiefel⁷, Daniel Albert⁷, James Rosenbaum⁸ and Marcia Friedman¹, ¹OHSU, Division of Arthritis and Rheumatic Diseases, Portland, OR, ²OHSU, School of Public Halth, Portland, OR, ³OHSU, Oregon National Primate Research Center, Portland, OR, ⁴OHSU, Division of Arthritis and Rheumatic Diseases, Porltand, OR, ⁵OHSU, Casey Eye Institute, Porrtland, OR, ⁶Mayo Clinic, Division of Anatomic Pathology, Rochester, MN, ⁷OHSU, Casey Eye Institute, Portland, OR, ⁸Corvus Pharmaceuticals and Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in people over 50 years old and is a clinical diagnosis bolstered by pathologic findings on temporal…
Abstract Number: 0367 • ACR Convergence 2024
Opinions from Rheumatoid Arthritis Patients and Providers on Discontinuing Methotrexate in Stable Disease
Peri Newman¹, Sharon Banks¹, Rayford June², Erik Lehman³, Glennys Smith⁴, Vandana Rai⁴, Nicole Wilson⁴, Nancy Olsen⁵ and Tarun Sharma⁴, ¹Penn State Health, Hershey, PA, ²Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA, ³Penn State College of Medicine, Hershey, PA, ⁴Allegheny Health Network, Pittsburgh, PA, ⁵Penn State University/Milton S Hershey, Hershey, PA
Background/Purpose: The 2021 American College of Rheumatology guidelines for treatment of rheumatoid arthritis (RA) conditionally recommend a gradual discontinuation of methotrexate (MTX) over biologic discontinuation.…
Abstract Number: 2669 • ACR Convergence 2024
Dysferlin Autoantibodies Compromise Sarcolemmal Repair Capacity and Contribute to the Pathogenesis of Idiopathic Immune Myopathies
Hannah Bulgart¹, Kassidy Banford², Shane Bruckner³, Kevin McElhanon², Nicholas Young¹, Brian Paleo², Eric Beck², Rohit Aggarwal⁴, Chester Oddis⁵, Braden Zeno⁶, Wael Jarjour⁷ and Noah Weisleder³, ¹The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University, Columbus, ³Ohio State University, Columbus, OH, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Ohio State University, upper arlington, OH, ⁷The Ohio State University, Columbus, OH
Background/Purpose: Idiopathic immune myopathies (IIMs) are a group of autoimmune diseases that produce chronic inflammation and degeneration of skeletal muscle structure and function. One process…
Abstract Number: 0801 • ACR Convergence 2024
Neutrophil Activation as a Novel Marker of Lung Disease in Rheumatoid Arthritis
Jia Shi¹, Yang Wu¹, Ting Wang², Chen Yu³, qian wang⁴, Xinping Tian⁵, Mengtao Li⁴, Kristen Demoruelle⁶, Joshua Solomon⁷ and Christian Lood², ¹University of Washington, Seattle, ²University of Washington, Seattle, WA, ³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ⁴Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶University of Colorado Anschutz Medical Campus, Golden, CO, ⁷National Jewish Health, Denver, CO
Background/Purpose: Neutrophil activation is seen in rheumatoid arthritis (RA), but its involvement in RA interstitial lung disease (RA-ILD) is not clear. Levels of N-formyl methionine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].